ANTX Stephen David Prior sells $4K worth of shares
Feb 01, 2026, 5:38 AM
0.00%
What does ANTX do
AN2 Therapeutics, a biopharmaceutical company based in Menlo Park, California, focuses on developing treatments for serious infectious diseases, with epetraborole as a potential oral treatment for non-tuberculous mycobacterial lung disease. The company went public on March 25, 2022, and employs 41 people.
Stephen David Prior sold 3,604 shares of ANTX on 5 January at $1.00 per share, worth a total of $4K. They now own 61,944 ANTX shares, or a 5% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.